De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sage Therapeutics Beheer
Beheer criteriumcontroles 2/4
Sage Therapeutics' CEO is Barry Greene, appointed in Dec 2020, has a tenure of 3.83 years. total yearly compensation is $6.24M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $614.19K. The average tenure of the management team and the board of directors is 3.9 years and 9.2 years respectively.
Belangrijke informatie
Barry Greene
Algemeen directeur
US$6.2m
Totale compensatie
Percentage CEO-salaris | 12.8% |
Dienstverband CEO | 3.8yrs |
Eigendom CEO | 0.1% |
Management gemiddelde ambtstermijn | 3.9yrs |
Gemiddelde ambtstermijn bestuur | 9.2yrs |
Recente managementupdates
Recent updates
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
Jul 25Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust
Jul 12Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$446m |
Mar 31 2024 | n/a | n/a | -US$503m |
Dec 31 2023 | US$6m | US$799k | -US$541m |
Sep 30 2023 | n/a | n/a | -US$656m |
Jun 30 2023 | n/a | n/a | -US$592m |
Mar 31 2023 | n/a | n/a | -US$558m |
Dec 31 2022 | US$6m | US$761k | -US$533m |
Sep 30 2022 | n/a | n/a | -US$510m |
Jun 30 2022 | n/a | n/a | -US$503m |
Mar 31 2022 | n/a | n/a | -US$484m |
Dec 31 2021 | US$59m | US$735k | -US$458m |
Sep 30 2021 | n/a | n/a | US$642m |
Jun 30 2021 | n/a | n/a | US$666m |
Mar 31 2021 | n/a | n/a | US$637m |
Dec 31 2020 | US$836k | US$53k | US$606m |
Compensatie versus markt: Barry's total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.40M).
Compensatie versus inkomsten: Barry's compensation has increased whilst the company is unprofitable.
CEO
Barry Greene (61 yo)
3.8yrs
Tenure
US$6,237,491
Compensatie
Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 3.8yrs | US$6.24m | 0.14% $ 614.2k | |
CFO & Treasurer | 11.6yrs | US$1.98m | 0.11% $ 506.5k | |
Senior VP | 9.1yrs | US$2.15m | 0.021% $ 92.3k | |
Chief Business Officer | 3.1yrs | US$2.28m | 0.0082% $ 36.0k | |
Chief Medical Officer | 2yrs | US$1.27m | 0.018% $ 77.5k | |
Chief Technology & Innovation Officer | 3.9yrs | geen gegevens | geen gegevens | |
Chief Scientific Officer | 1.2yrs | geen gegevens | geen gegevens | |
Director of Investor Relations | no data | geen gegevens | geen gegevens | |
Chief People & Experience Officer | no data | geen gegevens | geen gegevens | |
Senior Vice President of R&D Strategy and Business Management | 7.5yrs | geen gegevens | geen gegevens | |
Senior Vice President of Technical Operations | 3.9yrs | geen gegevens | geen gegevens | |
Senior Vice President of Drug Safety & Pharmacovigilance | no data | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: SAGE's management team is considered experienced (3.9 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 4yrs | US$6.24m | 0.14% $ 614.2k | |
Independent Director | 10.1yrs | US$440.05k | 0% $ 0 | |
Independent Director | 10.4yrs | US$435.05k | 0.0047% $ 20.5k | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Chair of the Board | 8.3yrs | US$417.55k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
9.2yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: SAGE's board of directors are considered experienced (9.2 years average tenure).